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Abstract: Aim and Objective: Vinca domain of tubulin protein is the potential target for different 
microtubule targeting drugs (MTD). However, its binding mechanism and structure-activity-
relationship (SAR) is not well understood in terms of ligand-receptor interactions and structure 
functionality requirements. This limits the exploitation of vinca domain for developing novel clinical 
leads. Herein, as a progressive step towards the exploration of this target, we rendered the in-silico 
insight through the development of a robust pharmacophore model followed by the QSAR, 
Molecular Docking and Molecular Dynamics (MD) simulations. Furthermore, the study was 
undertaken to identify potent inhibitors that can inhibit vinca domain of tubulin.  
Materials and Methods: Utilizing the well-defined tubulin polymerization inhibition activities, 
common pharmacophore hypotheses were constructed and scored for their rankings. The hypotheses 
were validated by 3D-Atom based QSAR and tested for various statistically relevant metrices. 
Thereafter, virtual screening was performed with ZINC natural product database and the screened 
hits were evaluated for structure-based studies via molecular docking and molecular dynamics 
simulations.  
Results: The predictive 3D-QSAR based pharmacophore model consists of two hydrogen bond 
acceptors (A), two hydrogen bond donors (D) and one hydrophobic (H) group. Significance of the 
model was reflected from the statistical parameters viz. r
2
 = 0.98, q
2
 = 0.72, F = 562.9, RMSE = 0.11 
and Pearson-R = 0.87. Further, the docking scores of the retrieved hits deciphered that the ligands 
were adequately bound in the pocket. Moreover, RMSD fluctuations of protein (1.0 to 1.75A) and 
ligand (0.3 to 2.3 Å) in molecular dynamics simulations insinuate towards the conformational and 
interactions stability of the complexes.  
Conclusion: The quantitative pharmacophore model was developed from range of natural product 
scaffolds in order to incorporate all the complimentary features accountable for inhibition. The 
obtained hits were found to occupy similar binding region and superimpose well over the reference 
ligand. Therefore, it can be concluded that hierarchical combination of methods exploited in this 
study can steer the identification of novel scaffolds. Moreover, the rendered hit molecules could 
serve as potential inhibitory leads for the development of improved inhibitors targeting Vinca 
domain. 
Keywords: Pharmacophore, microtubules, antimitotic, virtual screening, natural products, molecular docking, QSAR.   
1. INTRODUCTION 
 
Microtubule targeting drugs (MTD) are characterized by 
a variety of compounds targeted against microtubular  
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proteins that form major structural components of the cell  
[1]. These microtubules are highly dynamic hollow 
cylindrical polymers composed of α, β-tubulin globular 
protein subunits vital for the cellular proliferation, signaling 
and for the cellular movements [2]. Despite forming major 
cytoskeleton component, it plays key role in intracellular 
transportation, maintaining cellular shape, and in cell 
division [3]. Attributable to the multifarious biological 
 
 
 
 
  
implications, it exemplifies as potential pharmaceutical 
target for diverse group of anti-parasitic and anticancer drugs 
[4]. It can also be argued that microtubules represent as the 
only single best non-DNA cancer target identified till date 
[1, 5, 6]. Hence, for boosting the advances in anticancer 
therapy, research for microtubule/tubulin therapeutics is of 
central contour [7-9]. The three-dimensional structure of 
tubulin protein consists of two internal β-sheets surrounded 
by several α-helices arranged parallel to the cylindrical axis 
and forms a stable heterodimer [10]. It undergoes 
polymerisation by nucleation-elongation mechanism and 
exhibits dynamics with the expense of energy provided from 
the GTP hydrolysis at the N-terminal [11, 12]. 
 
In particular, the microtubule dynamic (tread milling and 
dynamic instability) execute critical role in the polymeric 
assembly and functioning of mitotic spindle. Specifically, 
rapid dynamic microtubules are obligate for the orchestration 
of mitotic events like congression, equipartitioning and 
chromosomal bipolar alignment. This essential dynamic 
equilibrium is affected by treatment of agents that can shift 
equilibrium between polymerisation and depolymerisation 
phases [13]. Hence, subsequent binding of drugs with tubulin 
attenuates microtubule stability, dynamics and other 
functions including inhibition of mitosis during 
metaphase/anaphase stage. This in turn led to halting of the 
cellular transition by suppressing spindle dynamics followed 
by mitotic blockage and cellular apoptosis [14]. Likewise, a 
large number of chemically diverse compounds have been 
developed as a potential class of chemotherapeutic drugs 
against cancer [15-17]. Intriguingly, targeting of such drugs 
can be originated via three possible ways/sites (1) Vinca 
domain (depolymerization) (2) colchicine site; or (3) taxane 
site (depolymerisation inhibitor) [18]. Vinca domain is 
represented by inter-dimeric space between β-subunit of one 
dimer and α-subunit of another dimer. However, colchicine 
domain is well explored and targeted by ligands like 
colchicine, combrestatin, 2-methoxy estradiol etc. The third, 
taxane site is typified by drugs like taxanes, paclitaxel and 
docetaxel that bind to the lumen of the β -subunit of the 
polymerized microtubules [19]. 
 
Vinca binders are specifically classified into ″Vinca site″ 
binders and ″peptide site″ binders in the Vinca domain of 
tubulin [20]. Vinca site comprise of vinblastine, vincristine, 
vinorelbine etc. and peptide site represented by dolastatins, 
hemisterlins, helichondrins etc. Based on competitive and 
noncompetitive mode of action, the vinca alkaloids can be 
 
further categorized into various classes as mentioned in Fig.  
(1) [12, 21, 22]. 
 
Among the clinical MTD, most drugs are presumed to 
bind with colchicine domain, as the understanding of the 
Vinca domain is still obscurely explored. Owing to the 
increasing menace of drug resistance, toxicity and other side 
effects of MTDs, there is an urgent need to map vinca 
domain for developing new therapeutics [13, 23, 24]. 
 
It is also important to mention that there are various 
studies that attempted to model and design antimitotic 
compounds [25-28]. However, such studies did not address 
the complicacy of vinca site. The present study has been 
carried out with diverse scaffolds to generate pharmacophore 
model and for screening antimitotic/anticancer compounds. 
Taking into account the dominance of natural product based 
known tubulin inhibitors [29], ZINC natural product 
database [30, 31] was used in the present study. Distinctly, to 
avoid any uncertainties associated with model building, 
modelling has been carried using the polymerisation 
inhibition activities of pure tubulin protein (IC50). The study 
would be certainly useful for opening new vistas to design 
new antimitotic and anticancer therapeutic. To the best of 
our knowledge, this is the first pharmacophore based 3D-
QSAR study of Vinca binders. 
 
2. MATERIALS AND METHODS 
 
2. 1. Computational Details 
 
Pharmacophore modelling and ligand based virtual 
screening studies were carried out using PHASE, version 4.1 
[32, 33] module incorporated in Schrödinger Suite 2014-4  
[34] installed on High Performance Computing system of 48 
Xenon core with CentOS operating system. Discovery 
Studio v4.0 was used to clean and minimize the hits that 
were subsequently imported for FlexX docking on LeadIt 
2.1.8 [35]. 
 
2.1.1. Dataset of Vinca Binders 
 
Literature and databases search divulge the substantial 
evidences of only 26 compounds with well-defined tubulin 
polymerization inhibition activities (IC50) (Fig. S1). The 
limited but structurally diverse dataset was selected based on 
the following criteria: (1) all compounds with inhibitory 
activity specifically against tubulin proteins and their binding 
at Vinca domain of tubulin, (2) similar biological assay  
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Fig. (1). Depiction of various classes of Vinca alkaloids targeting Vinca site of the tubulin protein [12, 15, 16]. 
  
conditions; and (3) ligands may act competitively or non-
competitively with the binding of other Vinca alkaloid. 
Thereafter, experimental activities (IC50) were converted to 
molar units and further to the negative logarithmic unit by 
converting into the pIC50 by employing Equation 1. 
 
Eq.1 
 
where, IC50 is the micro molar concentration of the inhibitor 
producing 50% inhibition. The obtained pIC50 values were 
considered as the dependent variable throughout the 
modelling studies (Table 1). 
 
2.1.2. Processing of Chemical Structures 
 
The structure of the compounds were sketched using the 
builder panel in Maestro followed by cleaning and 
optimization using Ligprep [36] module that performs 
addition of hydrogens, adjusts bond length and angles, 
checks for the chiralities, tautomers, stereochemistries and 
 
Table 1. Dataset of Vinca domain binders extracted from 
 literature with their activity of tubulin 
 polymerization.     
     
No. Compounds  IC50(µm) References 
      
      
1. Vinblastine  1.7  [39] 
      
2. Vincristine  1.7  [39] 
      
3. Vindesine  1.4  [39] 
      
4. Vinfosiltine  2.4  [39] 
      
5. Vinorelbine  1.7  [39] 
      
6. Vinflunine  3.1  [39] 
      
7. Dolastatin 10  1.2  [40] 
     
8. Dolastatin 10 (Isomer 2) 1.4  [40] 
     
9. Dolastatin 10 (Isomer 5) 2.6  [40] 
     
10. Dolastatin 10 (Isomer 8) 28  [40] 
     
11. Dolastatin 10 (Isomer 15) 40  [40] 
      
12. Dolastatin 15  23  [40] 
      
13. ER-076349  5.7  [41] 
     
14. EribulinMesylate (E7389) 11  [42] 
     
15. E7974(hemisterlinanalog) 3.9  [43] 
     
16. ER-809878(hemisterlinanalog) 4.8  [43] 
     
17. EV-812906(hemisterlinanalog) 2.2  [43] 
      
18. Sablidotin (TZT-1027)  2.2  [44] 
      
19. Halichondrin B  7.2  [45] 
      
20. Homohalichondrin B  20  [45] 
      
21. Cryptophycin 1  2.7  [46] 
      
22. Diazonamide A  0.33  [46] 
      
23. Phompsin A  1.4  [45] 
      
24. Maytansine  3.4  [45] 
      
25. Rhizoxin  6.9  [45] 
      
26. Spongistatin  3.6  [47] 
       
 
ring conformations. The atomic charges were assigned by 
Optimized Potential for Liquid Simulations (OPLS-2005) 
force field [37] and possible ionisation states were generated 
at a pH of 7.0. The ConfGen module integrated in PHASE 
was used to generate energy minimized bioactive conformers 
with OPLS-2005 force field at a cut-off RMSD of 1.0Å [38]. 
Conformers were also filtered through a relative energy 
window of 104.6 kJ/mol, with the considerations of 1000 
maximum number of conformers and pre-and post-
minimization steps of 1000 per ligand. 
 
2.1.3. Pharmacophore Model Generation 
 
Ligand based 3D-Pharmacophore model was developed 
to identify the minimal fundamental pharmacophoric 
features that govern the biological activity. Before the model 
building, the ligands were categorized into actives and 
inactives by applying proper threshold in terms of activity 
and structural diversity. Six active and five inactive 
molecules were ascribed. Importantly, the inactive 
compounds are used to validate the generated hypotheses as 
their features does not dictate for any activity [48]. However, 
inactive set was used to adjust the hypothesis scores that 
reflect the quality of the model [49]. 
 
2.1.3.1. Creating Pharmacophore Sites 
 
A set of pharmacophoric features are used to represent 
ligand structure and a set of site points in 3D space to 
develop a common pharmacophore hypothesis (CPH). These 
site points are characterized by type, location and 
directionality [32]. Moreover, site points represent various 
chemical features that possibly facilitate the non-covalent 
binding of ligand to the target. PHASE uses six types of 
built-in pharmacophoric features: H-bond donor (D), H-bond 
acceptor (A), hydrophobic group (H), negatively charged 
group (N), positively charged group (P), and aromatic ring  
(R). All pharmacophoric sites are internally signified by a set 
of SMARTS pattern and assigned one of the three possible 
geometric representations: point, group or vector [50]. 
However, feature definition rules are applied to map the 
positions of the pharmacophore sites. 
 
2.1.3.2. Generating Common Pharmacophores 
 
A set of active ligands and their conformations were used 
to build the 3D pharmacophore model (active analog 
approach) [51]. As per the IUPAC recommendations, a 
pharmacophore is ″the ensemble of steric and electronic 
features that is necessary to ensure the optimal 
supramolecular interactions with a specific biological target 
structure and to trigger (or to block) its biological 
response″[52]. Therefore, to augment the stereo-electronic 
features in the form of pharmacophore model, PHASE 
algorithm was used. It is based on analyzing k-point 
pharmacophores culled from the conformations of actives 
constraining to match on to all k-sites [32]. Common k-point 
pharmacophore feature were perceived from a set of variants 
(set of feature types) and from different subset of actives 
using tree-based partitioning method that assembles similar 
pharmacophores on the basis of their inter-site distances, i.e., 
the distances between pairs of sites in the pharmacophore. 
* Inhibition Of Tubulin Polymerization IC50 (µm) 
  
Five-point common pharmacophore were generated with the 
requirement that all active ligands should match. The 
hypotheses were generated with inter-feature distance of 
1.5Å by employing systematic variation of number of sites 
and number of matching active compounds. 
 
2.1.3.3. Scoring Hypothesis 
 
A set of hypotheses that survives in partitioning 
procedure within the space of intersite distances undergo 
scoring for conceding best alignment of active ligands. The 
scoring allows ranking of different hypothesis and makes 
rational choices among the hypothesis for further 
investigations. Scoring was conducted using default 
parameters for site, vector, and volume terms [32]. The final 
scoring function i.e., survival score contains the following 
terms:  
S = WsiteSsite+ WvecSvec + WvolSvol + WselSsel + Wmrem 
 
where and are the predicted and actual activities of the ith 
molecule in the training set respectively, is the average 
activity of all the molecules in the training set. However, the 
external validation was computed from the test compounds 
(q
2
) using the equation: 
 
   
 
  
 
     
Eq.3        
           
where and are the predicted and actual activities of the ith 
molecule in the test set respectively, is the average activity of 
all the molecules in the training set. 
 
In addition, the model was also evaluated for survival 
score, adjusted survival scores, Pearson-R coefficient and F 
distribution values. Furthermore, the test set was externally 
validated [56-58] for various essential parameters like ,  
and k value using XternalValidationPlus 1.0 [59] by 
employing the following equations:  
 
where W’s are weights and S’s are scores, Ssite represents an 
alignment score and Svec represents vector score. Svol denotes  
volume score based on overlay of van der Waals models of 
non-hydrogen atoms. Ssel signifies the selectivity score that 
accounts for the number of molecules that match the 
hypothesis. The best common pharmacophore hypothesis 
was selected depending on the adjusted survival scores 
among all the hypotheses. 
 
2.1.4. Pharmacophore Model Validation by 3D-QSAR 
 
The top-scored hypothesis was used to generate atom-
based 3D-QSAR model for explaining structure-activity 
relationship. For QSAR prediction, the dataset was randomly 
divided into training and test sets. In particular, test set 
should be a subset of the training set in terms of structural 
diversity and activity span. Out of 26 molecules, the dataset 
was randomly divided into a training set of 17 compounds 
and remaining in the test set. Furthermore, wide range of 
structural diversity of compounds in the test set legitimate us 
to evaluate the extrapolative accuracy of the 3D-QSAR 
models [53]. 
 
The QSAR models can decipher the positively and 
negatively contributing factors to the activity. In particular, 
PHASE uses grid based modeling, in which the spaces 
occupied by the aligned ligands were divided into cubes of 
typically 1Å on each side followed by binary valued 
occupancies (″bits″) treatment. Atom-based 3D-QSAR 
model was generated which treat molecule as a set of 
overlapping van der Waals spheres [54]. The models were 
generated with grid spacing set to 1Å. Thereafter, the test set 
molecules were aligned and their activities were predicted 
through the regression analysis [55]. Four factor Partial Least 
Squares (PLS) regression was applied during the QSAR 
model building. The predictive power of the model was 
tested for internal stability against test set compounds and 
examined for external validations. Internal Validation was 
carried out using the leave-one-out ( , LOO) method 
employing the following equation 2. 
 
     
 
  
Eq.2     
       
  
  
  
  
 
  
Eq.4    
  
 
         
            
  
       Eq.5 
 
 
  
 
    
   
 
     
            
Where, is the average of the predicted value of compounds in 
the dataset. The regression of against through the origin 
should have k nearer to 1 and the slope can be calculated 
using Equation 6. 
 
Eq.6 
 
 
2.1.5. Applicability Domain Study (AD) 
 
QSAR applicability domain study was performed to 
analyse the significance of the model for reliable predictions 
[60]. It represents structural or biological space and 
physicochemical knowledge information based on the 
training set of the model that is used for the prediction of test 
compounds. Moreover, it also specifies the scope of the 
proposed model and defines model limitations with respect 
to structural domain [61]. Using this method, compounds 
beyond the scope of model can be delineated and retracted 
from the training set. Further investigation of the dataset was 
employed by mathematical means for the biological 
conception that model compounds should possess structural 
correlation in regard to active site in which they fit. Here, we 
have used the algorithm and methodology proposed by Roy 
et al. to define training set outliers and recognition for the 
compounds existing outside the AD [62, 63]. 
 
2.1.6. Virtual Screening 
 
  Virtual screening was performed to retrieve hits from 
ZINC natural products database (84215 compounds) using 
the pharmacophore model [64, 65]. The IBScreen NP 
database was downloaded (http://zinc.docking.org/) in .mol2 
format and prepared for fixing suitable geometries using 
Ligprep wizard. Subsequently, advanced pharmacophore 
screening workflow of PHASE was used to map and rank 
the database compounds on the selected hypothesis. Per 
rotatable bond 10 and maximum of 200 conformers of each 
library compounds were generated, within a relative energy 
window of 10.0 kcal/mol. To gauze the best mapping and 
. 
 
realistic outcomes, thorough mode of ligand sampling was 
used. 
 
2.1.7. Molecular Docking 
 
Screened hits obtained from ligand-based method 
(pharmacophore) were further studied for structure-based 
studies (docking) using LeadIt 2.1.8 [35]. The program uses 
FlexX approach and considers ligand flexibility with 
changing ligand conformations. It uses incrementally build 
up algorithm and starts docking with base fragment [66]. 
However, after placing the base fragment, whole ligand is 
built up by adding remaining fragments on to it. The protocol 
purely considers protein as rigid. 
 
The study was planned to investigate the intermolecular 
interactions between the hits (ligands) and the target i.e., 
Vinca binding domain of the tubulin protein. The X-ray 
crystal structure of stathmin like-domain complex (RB3-
SLD) [PDB entry code: 1Z2B] was retrieved from the 
Protein Data Bank (http://www.rcsb.org) [67, 68]. Prior to 
docking, ligands were pre-processed using prepare ligand 
wizard in Accelrys Discovery Studio 4.0. The active site of 
receptor was defined in LeadIT considering a radius 10 Å 
(from the centroid of the co-crystallised ligand i.e., 
vinblastine). The method uses empirical scoring function 
(LeadIT score) which computes the binding energy (ΔG) of 
the ligand-protein complex by following equation. 
 
=
   +      
×
    
=
   
+
       lipocount *  R, Δα Here, *  R, Δα is  a  
scaling  function  penalizing  
deviation from ideal geometry. is the number of free 
rotatable bonds that are confined in the complex [69]. The 
terms ΔGo and ΔGlipo are adjustable parameter and lipophilic 
contact energy respectively. Finally, the poses containing the 
highest score were selected for analysing the ligand-receptor 
interactions. 
 
2.1.8. Molecular Dynamics (MD) Studies 
 
MD simulations were performed by using Desmond 
version 2.0 (Academic Version) [70-72] which utilises 
neural territory method for exploiting greater degree of 
computational parallelism [73]. The highest scored retrieved 
hits from virtual screening and docking were examined by 
MD for over a period of 10ns. OPLS-2005 force field 
parameterizations [37] were used to model interactions and 
conformational behavior in a solvation system of SPC 
(Simple Point Charge) water molecules as solvent [34]. The 
solvation system was constructed with orthorhombic 
boundary condition (10 Å × 10 Å × 10 Å) ensuring that the 
whole complex covered. Thereafter, the system was 
neutralised by adding 87 sodium ions (73.175 mM) and 60 
chloride ions (50.465 mM) to balance the net charge of the 
system. Prior to MD, the solvated system (comprise of 77819 
atoms) was allowed to pre-equilibrate using default 
relaxation parameters in a series of restrained steps as 
implemented in Desmond. 
 
The electrostatic interactions were treated by particle-
mesh Ewald method for long range whereas cut-off of 9Å 
was used for short range van der Waals and coulombic 
interactions [74]. Further, Isothermal-Isobaric NPT ensemble 
 
was used with the temperature of 300K (Nose-Hoover 
thermostat) and 1bar pressure [75]. Subsequently, the MD 
trajectory was recorded at an interval of every 10ps for over 
a period of 10ns to capture 1000 MD frames. The structural 
changes and dynamic behaviour of the protein were analyzed 
by calculating the RMSD and energy. 
 
3. RESULTS AND DISCUSSION 
 
Rationale behind this work was to cognise the structural 
features and pharmacophoric requirements critical for the 
ligand binding at Vinca site of the tubulin. Furthermore, to 
identify the novel compounds using the pharmacophore 
based virtual screening. 
 
3.1. Pharmacophore Modelling 
 
The reported modelling work employs PHASE 3D-
QSAR formalism that has various advantages over to other 
older approaches. Particularly, it applies tree-based 
partitioning algorithm to generate bit string representations 
of the ligands and bi-directional clustering approach to 
distinguish multiple binding modes [76]. Several six, five 
and four-point pharmacophore hypotheses were generated 
using six actives (>5.769) and five inactives (<4.958). The 
selected ligand molecules (actives/inactives) were used to 
test and generate the hypotheses and for defining the 
excluded volumes of inactives [77]. The remaining 
molecules of the dataset were used to further validate and 
authenticate the pharmacophore model. 
 
All the possible hypotheses from the set of actives and 
identical sets of features with similar spatial arrangement 
were congregated to recognize a common pharmacophore. 
Subsequently, a list of 71 combinations of site feature 
variants were obtained as possible Common Pharmacophore 
Hypotheses (CPH) having at least five site features that must 
match on four active molecules. These variant combinations 
were scored by active and inactive compounds to identify a 
set of hypotheses to extract best alignment of all chosen 
actives. The three and four featured CPHs were rejected as 
they were unable to define the complete binding space and 
regression contours. Overall, 326 possible CPHs were 
generated and subjected for rigorous scoring analysis for site, 
vector, and volume. In scoring, biological activity of 
compounds (pIC50) was included in the score with a weight 
of 1.0, however reference relative conformational energy 
(kJ/mol) was incorporated with a weight of 0.01. The 
resulting hypotheses were scored with respect to the fixed 
actives and inactives. The summary of the hypotheses 
survived with their survival scores are listed in Table 2. The 
hypothesis AADDH.5352 was selected due to its superiority 
of scores and ability to distinguish from actives and 
inactives. The hypothesis was represented with two donor 
features (D), two acceptor features (A) and one hydrophobic 
feature (H) (Fig. 2). Feature representations with inter-
feature distances (depicted in Fig. 2a) and inter-feature 
angles (Table S3, †ESI) were the principal attribute that 
distinguished active from inactives. 
 
Larger value of the survival- inactive score i.e., 2.127 
indicate that the hypothesis can successfully discriminates 
actives and inactives substantially. The greater value of Post-
Hoc score for this hypothesis (2.65) specifies that the model 
  
Table 2.  Score of different hypothesis generated in pharmacophore building.     
          
 
ID Survival 
Survival - 
Post-hoc Site Vector Volume Energy 
 
 
Inactive 
 
         
          
          
 AADDH.5352** 2.864 2.127 2.654 0.5 0.806 0.34 8.82  
          
 ADHHP.169 2.857 1.482 2.647 0.46 0.948 0.23 14.70  
          
 ADHHP.153 2.854 1.674 2.645 0.46 0.947 0.24 16.51  
          
 ADHHP.168 2.853 1.439 2.643 0.46 0.945 0.24 2.96  
          
 ADHHP.172 2.847 1.439 2.637 0.45 0.944 0.24 8.89  
          
 ADHHP.154 2.838 1.396 2.628 0.44 0.942 0.24 7.02  
          
 ADHHP.170 2.829 1.66 2.619 0.44 0.941 0.24 20.39  
          
 ADHHP.2 2.827 1.393 2.617 0.43 0.935 0.25 24.91  
          
 ADHHP.171 2.821 1.626 2.611 0.43 0.938 0.24 16.50  
           
** Selected hypothesis used for modelling studies 
 
was highly reliable. Moreover, the Site and Vector Score 
values (0.50 and 0.80 respectively) further endorse that the 
site points and corresponding functionalities were 
superimposed well. The mapping of AADDH.5352 over to 
the highest active compound in Fig. (2b) further insinuates 
that most of the features completely overlap onto the ligand 
functionalities. Conversely, mapping on the most inactive 
molecule in Fig. (2c) was unable to overlay on most of the 
ligand functionalities. This observation led to the conclusion 
that selected pharmacophore model can distinguish inactive 
ligands from the set of actives. It can be anticipated that 
chemical structure posing these feature with the given stereo-
electronic requirement and at the cited region in particular, 
would probably adjusts systematic structure-activity 
relationships for tubulin inhibition activity [78]. Therefore, 
screening with Virtual and high throughput methods using 
pharmacophore can lead to the identification of potent, 
efficacious and orally bioavailable analogues [79]. In 
addition, the presence and absence of such groups can be 
quantified by building the QSAR model that can be used to 
screen the matches in the database as well as identification of 
the functional groups contributing negatively or positively to 
activity. 
 
3.2. 3D-QSAR Modelling 
 
On the way to correlate the biological activity as 
dependent variable with the binary value (ligand descriptors) 
as independent variable, atom based 3D-QSAR model was 
generated using the four factor PLS [80]. Increase in PLS 
components beyond four did not improve the statistics or 
predictive ability of the model [81]. The best model was 
selected corresponding to second PLS factor with hypothesis 
AADDH.5352 on the basis of relatively high value of cross 
validation coefficient i.e., 0.729 and low RMSE. QSAR 
analysis shows that the selected pharmacophore hypothesis 
display good correlation with statistically significant values 
of = 0.986 and standard deviation (SD) 0.206. Moreover, 
significance of model was further supported by meaningful 
RMSE 0.110, Pearson-R 0.879 and F-statistics value 562.9 
(Table 3). As shown in Table 3, the statistics 
 
lies in good agreement with large value of F and small value 
of P; an indication of a high degree of confidence. The 
selected best model was further validated for their external 
predictive reliability using Pearson coefficient of correlation 
(Pearson-R) which was found to be 0.879. 
 
Further, the goodness and model predictability was 
analyzed by and metrics as depicted in Table 4. The 
correlation plots between the predicted activity of training 
set molecules exhibits satisfactory linear correlation with 
minor differences in experimental/predicted activities (Fig. 
S2, Table S1). 
 
3.3. QSAR Contour Plot Analysis 
 
PHASE renders the additional insights into structure-
activity relationship (SAR) by visualizing the effects due to 
respective pharmacophoric feature and their associated 
positive and negative regression coefficients. The 
visualization was performed by contour plots to perceive and 
recognize the discrete vital pharmacophoric requirements at 
spatial sites of structure. Moreover, these maps identify the 
presence and absence of essential chemical feature. 
Nonetheless, this allow identification of those positions that 
require a particular physicochemical property to enhance 
bioactivity of a ligand [82]. The contour plots represent 
positive and negative activity coefficients of (a) hydrogen 
bond donor, (b) electron withdrawing property, (c) 
hydrophobic/non-polar and (d) negative ionisable properties. 
Positive and negative contributions are depicted by blue 
cubes and red cubes respectively. Further, owing to high 
structural diversity, it was quite difficult to display the 
pharmacophore model on all ligands or the subsets of 
ligands. Therefore, we have depicted the contour plot of 
most active ligand i.e., diazonamide (Fig. 3) for better 
understanding of the groups substitution effects. Moreover, it 
can illustrate the spatial site points where a particular 
functionality directs the activity. In Fig. (3a) for H-bond 
donor, blue contour situated at –OH group (D11) and –NH 
functionality nearby 1,3 oxazole ring whereas it was 
unfavourable around dimethyl group. Fig. (3b) displays 
contour map for hydrophobic property and the blue contours 
mainly located near to the bridged carbon, on chloro group 
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Fig. (2). Stereoviews of the best pharmacophore model: a) Common pharmacophoric site features with inter-site distances between the 
pharmacophoric points (All distances are in Å unit), b) mapping of AADDH.5352over the highest active molecule, and c) mapping of 
AADDH.5352over the highest inactive molecule. 
 
Table 3. PLS statistical parameters of the selected 3D-QSAR model. 
 
ID # Factors SD r
2 
F P RMSE q
2 
Pearson-R 
         
         
AADDH- 
1 0.206 0.867 111.4 6.98E-09 0.135 0.56 0.86 
5352         
         
 2 0.069 0.986 562.9 1.49E-15 0.11 0.729 0.879 
         
 3 0.024 0.998 3042.7 4.20E-21 0.104 0.76 0.897 
         
 4 0.008 0.999 17851 8.90E-26 0.104 0.758 0.906 
         
SD, standard deviation of regression; r2 is for the regression coefficient; F is the ratio of the model variance to the observed activity variance (variance ratio); P, significance level of 
variance ratio.; RMSE, root-mean-square error, directly analogous to but based on the test set predictions or it can be better referred as R2pred, Pearson R value for the correlation 
between the predicted and observed activity for the test set; RMSE the RMS error in the test set predictions. 
 
and at the centre of the bulkier rings. The effect of positive 
ionic group demonstrates (Fig. 3c) that such groups were not 
required in between carbonyl of amide and dimethyl groups. 
Furthermore, Fig. (3d) depicts the contour map for electron 
withdrawing property that describes the favourable blue 
contours were demanded near to the oxygen of furan ring 
and –NH of amide group whereas opposed at chloro 
substitution position. 
 
Table 4.  External validation parameters  for  the  QSAR 
 model.        
          
    |  -  |   k  
          
         
 0.98583  0.9846 0.00017  0.99974  
         
Model acceptable criteria:  >0.5;  >0.5; |  -  |<0.3) and 0.85 ≤ k ≥1.15  
 
3.4. Applicability Domain (AD) Study 
 
The study was conducted by standardization approach  
[63] to find compounds that resides outside the AD. The 
result shows that there were no any X-outliers in training and 
test set which eliminate the chances of uncertainty associated 
with the predictions. This also substantiates that training set 
compounds possess some functional correlation in terms of 
structure and their modelled 3D descriptors and modelled 
response resides within the AD. 
 
3.5. Virtual Screening and ADME Properties Calculation 
 
Ligand based virtual screening [83] was executed 
utilizing the AADDH.5352 hypothesis as query to screen 
ZINC Natural product (NP) database to identify compounds 
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Fig. (3). Contour maps for 3D-QSAR models generated for most active Vinca binders i.e., Diazonamide A: hydrogen bond donor (a), 
hydrophobic (b), positive ionic (c) and electron withdrawing property (d) Blue contours correspond to the regions where the substitution of 
corresponding property group enhances the activity and vice versa for the red contours (Color illustration is available online). 
 
with similar physical and chemical properties 
(pharmacophore-based, descriptor-based) and likely to 
interact with the target [55]. Screening with the defaults 
parameters retrieved 596 molecules as hits that encompass 
the maximum fitness of 1.320 to 1.195 with four minimum 
number of site feature mapping threshold. Here, we majorly 
focussed on apprehending novel scaffolds inspired from 
diverse NP chemical functionalities. Nevertheless, these can 
be used as a guiding functionalities for the synthesis of 
promising new compounds. Overall, there were significant 
correlation between the fitness scores and tubulin binding 
activities of the compounds. Furthermore, receptor based 
virtual screening (docking) approach was also used to 
examine selectivity and for narrowing down the ligand-based 
screening results. Prior to docking studies, all the hits were 
examined for their ADME/T attributes. 
 
The ADME/T properties of the molecules are an essential 
guide for lead generation that avoids the failure of candidates 
in later stages attritions due to their poor pharmacokinetic 
profile [84]. The so called ‘drug likeness’ was estimated by 
calculating various ADME parameters using ‘QikProp’ 
program of Schrödinger Software [85] (Table S3). 
 
From 596 ligands, 559 compounds passed the ADME 
filters that follows Lipinski rule of five [86] and Verber rule 
of three [87]. 
 
Conspicuously, analysis of therapeutically relevant 
descriptor like QPlogPo/w, QPlogS, QPPCaco, QPlogBB, 
QPlogMDCK and polar surface area (PSA) also lies in the 
regimen of biological relevance. 
 
3.6. Molecular Docking 
 
Molecular docking study was performed using FlexX 
approach to study the ligand-receptor binding pattern [55]. 
The screened hits were analysed for interfering the tubulin 
assembly at Vinca domain located around RB3 stathmin 
peptide (RB3-SLD) [PDB entry code: 1Z2B] [67, 88, 89]. 
Moreover, the description of binding site was also taken 
from PDBsum [90] (Fig. S3). Based on >1.180 fitness score, 
99 ligands were used for docking among all the ADME 
filtered hits. The docked poses of the ligands that dominate 
in energetics and favorable interactions were analyzed, and 
found that ligands were adequately bound in the pocket with 
significant energy ranging from -30.298 to -11.778 kJ/mol. 
Scoring results for best fit twenty ligands in the binding 
pocket are tabulated in the Table 5. Simplifying the docking 
results for the docked poses of the compounds, we have 
chosen highest scored four representative ligands. 
Visualizations of the interacting amino acids with the ligands 
are depicted in Fig. (4). It was observed that the binding site 
and interacting amino acids were located in between chain B 
and C of tubulin protein. Intriguingly, most of the reference 
functionalities (present in co-crystallised structures) were 
found to associate with the docked screened hits. Depiction 
of the interaction maps and details of non-covalent 
interaction types are represented in ESI (Fig. S4 and Fig. S5, 
†ESI). Furthermore, structural alignment of hits in active 
domain of tubulin were also compared and contrasted as 
displayed in Fig. (5). Superimposition of screened hits on to 
the reference ligands illustrates that ligands own functional 
correlation and aligns very similar over to the known 
crystallized ligand. 
Table 5.  20 Best docked compounds enumerated after LeadIt        (Eq. 3) 
docking with their scores.              Compound ZINC72325117 possess significant ΔG score, 
                   
                   
-23.0kJ/mol which implies that it can exhibits substantial H- 
Name 
  
E_Total E_Match E_Lipo 
 
E_Clash 
  
ΔG 
 
      bonding and weak desolvation energies. Further, greater 
           
negative scores indicate weak desolvation penalties and ZINC72325117  -29.106 -26.429  -9.342  2.99   -23  
                   compound can easily ligated with the Vinca domain through 
ZINC59489217 
 
-30.298 -31.753 
 
-9.692 
 
7.734 
  
5 
 
      bonding interactions (ZINC12893948, ZINC32123863). In 
ZINC08764417  -25.53 -27.347  -7.419  4.584   -2  contrary, ligands that were solvated strongly and form 
                   
imperfect hydrogen bond of deviated length were able to 
ZINC12893948 
 
-25.45 -28.021 
 
-10.096 
 
8.36 
  
-20 
 
      
secured positivevalues. 
         
                            
ZINC02113067 
 
-25.029 -32.885 
  
-7.2 
 
8.175 
  
12 
          
                        
            
3.7. Molecular Dynamics Studies 
        
ZINC32123863 -24.962 -26.037  -12.198  5.737   -15          
ZINC04029355  -24.548 -34.471  -4.32  3.345   -11  To understand the structural integrity and for observing 
                   
ZINC12664540  -24.122 -21.634  -9.414  6.013   19  the interactions along the dynamic behaviour of the protein- 
                   
ligand complex, the MD simulations were executed with the ZINC02120497  -23.868 -24.544  -10.353  3.128   -1  
      
highest ranked hit molecule ZINC72325117. In addition, this                    
ZINC02134676 
 
-23.794 -28.709 
 
-9.411 
 
4.913 
  
5 
 
      was performed to examine the ligands dynamical behavior 
ZINC02112420  -23.349 -24.196  -8.788  4.799   16  and overall thermodynamic stability of the proposed hit 
                   
molecule. The RMSD values of the modelled protein as well 
ZINC96221829 
 
-23.289 -25.388 
 
-7.317 
 
1.909 
  
17 
 
      as ligand backbone atoms is plotted as a time-dependent 
                   
ZINC72325903 -22.968 -21.26   -10.967  3.985   -6  function in Fig. (6a). It is imperative from the results that 
ZINC06623887  -22.949 -29.04   -7.623  2.811   -10  there was constant RMSD deviation throughout the whole 
                   simulation run. In particular, fluctuations in the protein 
ZINC02140391 
 
-22.776 -28.052 
 
-7.229 
 
3.611 
  
2 
 
      RMSD was broadly ranged from 1.0 to 1.75A, however 
ZINC32124152  -22.767 -27.824  -5.663  4.13   -8  ligand RMSD was deviated from 0.3 to 2.3Å. The only 
                   
significant deviation was captured in between the time 
ZINC08879023 
 
-22.721 -22.474 
 
-12.83 
 
3.422 
  
-12 
 
      interval of 5 to 6ns. Overall, low RMSD indicate that the                    
ZINC09033913 
 
-22.699 -24.288 
 
-9.504 
 
9.968 
  
8 
 
     protein-ligand  complex  represents  a  stable  entity  and 
ZINC70672753  -22.388 -19.229  -14.175  6.462   -1  symbolizes for the possible tubulin inhibitor. The graph of 
                   the ligand RMSF, protein per residue contacts and change in 
ZINC96115293 
 
-22.332 -27.017 
 
-7.912 
 
2.215 
  
8 
 
      various molecular properties are depicted in supplementary 
                   
**Total Score (E_TOTAL), Total score of the docking solution; Match Score information.             
(E_MATCH), Contribution of the matched interacting groups; Lipo Score (E_LIPO), 
Further,  the  trajectory  was  post-processed  for Contribution of the lipophilic contact area; Ambig Score (E_AMBIG), Contribution 
of the lipophilic–hydrophilic (ambiguous) contact area; Clash Score (E_CLASH), investigating the key information of protein binding using 
Contribution of the clash penalty; ; Avg. Volume (AVG_VOL), Average volume of “simulation-interaction diagram” implemented  in  the 
protein/ligand overlap (for a description of the overlap test; Max Volume 
  
Maestro interface. Interaction types were grouped into four (MAX_VOL), Maximum volume of protein/ligand overlap (for a description of the 
overlap test and ΔG, Binding Free energy(kJ/mol) .          subtypes: hydrogen-bond, hydrophobic interactions, ionic 
                   bonds and water bridges. The results were profiled in the 
Ligand ZINC72325117 shows hydrogen bond with 
stacked bar plots in the Fig. (6c). The Fig. (6d) clearly 
deciphers that OH and carbonyl oxygen of quinazoline ring 
Ala247 C, Tyr224 B, Asn329 C, Asn249 C and significant 
and NH of amide linker engaged in developing the non- 
Van der Waals interactions with the Thr223 B, Val353 C, 
covalent interactions on the ligand. However, from 
 
the 
Val177 B, Gly354 C, Pro222 B, Ileu 355 C and Gly225 B  
protein active site residues Val177B, Ser178B and Asn101B 
residues. The total docking score was -29.106 kJ/mol with 
interaction remain intact for almost 77%, 31% and 41% of 
E_Match, E_Lipo and E_Clash score as -26.42, -9.342 and 
the 
 
total simulation time. Importantly, water-bridge 
2.99 respectively. However, ligand ZINC59489217  
interactions were observed in between the OH of 
 
the 
possesses the  total docking energy -30.298 kJ/mol with   
quinazoline and Asn101 of the vinca domain of tubulin 
lipophilic and matching scores of -9.62 and -31.75 kJ/mol 
protein (Fig. 6c). 
            
respectively. Among bonding interactions, H-bonding was             
                 
formed with amino acids Asp179 and Tyr224 in B chain 
4. DISCUSSION ON SCREENED HITS 
     
whereas Asn249 and Val177 residues in C chain. This      
comprehends that ligand fits adequately in the binding 
In the present scenario of ever increasing pressure on the 
pocket and would anticipates greater biological activity. 
pharma industry to accelerate its drug discovery process, 
Beyond the activity, specificity and sensitivity of screened 
current state-of-the-art computational 
 
methods seem to 
obtained ligands were also taken into consideration in order  
stipulate the goals [94, 95]. In particular, the hits retrieved in 
to prioritize the ligands as suggested by Chopra et al. [91]. 
the present study are difficult to contemplate by conventional 
Furthermore, Gibbs free energy of binding () were methods. Owing to this, we envisage the dominating 
also computed by HYDE assessment [92] for gauzing atom chemical functionalities involved in the ligand-receptor 
based hydration and desolvation effects of ligand-receptor binding event of the tubulin protein. The proposed hits (Fig. 
complex [93], by employing Equation 3.       S6)  were reported to comprise essential features and  
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Fig. (4). Docking poses and their interactions with the residue present in the active site of the protein (generated from visualizer, UCSF 
Chimera). 
 
 
 
 
 
 
 
 
 
 
 
a) ZINC59489217 b) ZINC72325117 c) ZINC08764417 d) ZINC12893948 
 
Fig. (5). Overlay of the reference ligand i.e., vinblastine (in green colour) over to the docked ligand inside the binding pocket of the tubulin 
protein (Color illustration is available online). 
 
orient in the binding site similar to the reference compounds. 
We anticipate that despite of comprising different structures 
or functional features, the hits possess healthy correlation in 
terms of biological potentials. Moreover, the presence of 
similar ligand-receptor interaction [67] minimizes the 
ambiguities associated with pharmacophore based virtual 
screening. 
 
CONCLUSION 
 
Structure-activity insight was rendered into the vinca 
domain of tubulin by the computational studies. The 
quantitative pharmacophore model was developed from the 
range of known active natural product scaffolds to 
 
incorporate essential complimentary features accountable for 
inhibition. The hypothesis meets the model acceptable 
criteria as observed from atom-based QSAR and 
applicability domain studies. Hence, the constructed model 
was subsequently employed for screening the diversified 
natural product database to uncover the analogs with 
improved potencies. We reported that the retrieved hits 
mimicked the binding pattern and orientation of the 
experimental pose. Through these results, it can be said that 
the hierarchical combination of methods can associatively 
steer the identification of novel scaffolds. The approach in 
principle proves the efficiency of the method and offer 
rationales for further lead optimization. 
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Fig. (6). Protein-Ligand RMSD and Contacts between the active site amino acids and the ligands during the course of 10ns MD simulation 
(a) Protein-Ligand RMSD plot (b) Number of total contacts; (c) Ligand atom percentage contribution with the protein residues; and (d) 
Interaction type of the protein residue contributing to the interaction. 
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